Application Note: A Cross-Platform Validation Study of EGFR-Activating Mutations in Non-Small Cell Lung Carcinoma Cells
2 May 2013
Mutations in the EGFR gene that lead to over expression and activity of the receptor have been associated with a number of cancers including Non Small Cell Lung Carcinomas (NSCLC). The constitutive activation of EGFR has prompted the development of EGFR tyrosine kinase inhibitors which can cause regression in NSCLC cells. In this scientific poster NSCLC cell lines harboring EGFR mutations, that confer either sensitivity or resistance to Gefitinib, were used to determine EGFR expression and activation as well as apoptotic marker expression following Gefitinib treatment.